Marc Gruninger, a director at Veraxa Biotech AG, has filed a report detailing two significant transactions involving the company's ordinary shares. This filing is noteworthy as it reflects Gruninger's personal investment strategy and could be seen as a vote of confidence in Veraxa's prospects.

Background

Veraxa Biotech AG, incorporated in Switzerland, operates in the pharmaceutical preparations sector. The company recently underwent a name change from Veraxa Biotech Holding AG on July 29, 2025. This filing, dated October 29, 2026, is part of Gruninger's ongoing disclosure requirements as a director.

What the Filing Says

According to the SEC filing (accession number 0001829126-26-011778), Gruninger reported two transactions:

“On October 27, 2026, Gruninger acquired 867 shares at a price of $0.98 each.”

“On October 28, 2026, he acquired an additional 9,133 shares at $1.00 each.”

Following these transactions, Gruninger now owns a total of 10,000 shares in Veraxa Biotech AG.

Impact

These transactions may affect investor sentiment regarding Veraxa Biotech AG. As a director, Gruninger's actions could be interpreted as a sign of confidence in the company's direction and future performance. Stakeholders, including investors and analysts, will likely monitor such transactions closely to gauge the company's stability and growth potential.

What's Next

The filing does not say what happens next.